Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%

Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline. 

from Health and Science https://ift.tt/lLOv8RA
https://ift.tt/gqL5frV
https://ift.tt/a6vzKXf